Georgia Tech Panama
Logistics Innovation & Research Center

Regional Hub for
Pharmaceuticals

Harmonizing Quality: A Global Perspective on Good Practices and Regulatory Synergy in Pharmaceuticals

Prepared by: Ricardo Espinoza

Georgia Tech Panama Logistics Innovation and Research Center

January, 2025

Harmonizing Quality: A Global Perspective on Good Practices and Regulatory Synergy in Pharmaceuticals

Georgia Tech Panama
Logistics Innovation & Research Center

Regional Hub for Pharmaceuticals

I. Introduction

The pharmaceutical industry is highly complex in terms of regulating and validating manufacturing processes due to the diverse chemical, physical, microbiological, and biopharmaceutical aspects of pharmaceutical products. Each stage must be meticulously controlled to consistently ensure the production and quality control of products, safeguarding public health. All parties involved, from pharmaceutical manufacturers to distributors, wholesalers, and transport companies, must adhere to legislation and regulations to uphold product standards.[1][2]

Good Manufacturing Practices (GMP) are a compilation of various guidelines and directives developed by international organizations in collaboration with the pharmaceutical industry and regulatory authorities. These standards aim to uphold efficacy, quality and safety in the production, distribution and consumption of pharmaceutical products. Compliance with GMP guidelines is essential for obtaining marketing authorization (MA) for drug approval and market launch.[3][4]

Established in 1941 and legally binding since 1973, GMP regulations serve as the primary framework for ensuring the quality of pharmaceutical products intended for human consumption. In response to evolving needs and safety requirements, the U.S. Food and Drug Administration (FDA) introduced GxP to encompass a wide array of activities, ensuring the manufacturing and control of pharmaceutical products according to required quality standards.[5][6][7]

GxP includes good practice guides governing preclinical, clinical, manufacturing, testing, storage, distribution, and post-market activities for regulated medical products. They are categorized into various sets of regulations, such as good laboratory practices (GLP), good clinical practices (GCP), good manufacturing practices (GMP), good pharmacy practice (GPP), good distribution practices (GDP), among others. Understanding the impact of these regulations on pharmaceutical standardization procedures requires a closer examination of each regulation separately.[8][9][10][11][12][13]

II. Overview of GxP-Regulated Subsectors

Good Manufacturing Practices (GMP)

Good Manufacturing Practices (GMP) are a set of rules and standards that govern the manufacturing of pharmaceutical products. They ensure uniform and controlled production in compliance with quality standards suitable for the intended use and marketing conditions. GMP guidelines cover all aspects of production, from materials and facilities to staff training and hygiene, aimed at preventing contamination, mixing errors, and production mistakes. **These guidelines are integral to the WHO certification scheme for pharmaceutical product quality in international trade** and serve as training material for government drug inspectors and industry personnel.

In the **EU**, current **Good Manufacturing Practices (cGMP)** are referenced instead of GMP. The flexibility of cGMP requirements allows each manufacturer to determine the best implementation methods, with the "C" emphasizing the need for manufacturers to stay current through guides, inspection directives, and FDA resources. Systems and equipment that were once considered advanced may no longer meet current standards, highlighting the evolving nature of manufacturing practices.[9][14][15][16][17]

Good Clinical Practice (GCP)

The Good Clinical Practice (GCP) guidelines ensure the ethical and scientific integrity of pharmaceutical research on human subjects, covering the design, conduct, analysis, and monitoring of clinical trials from early phases to post-registration studies. Compliance with GCP principles guarantees reliable clinical trial data and safeguards the rights, safety, and welfare of trial subjects as per the Declaration of Helsinki. These principles originate from the ethical foundations of the Helsinki Declaration and the Nuremberg Code, aiming to establish universal ethical standards for human research.

The World Health Organization (WHO) and the International Conference for the Harmonization of Technical Requirements for the Registration of Medicinal Products for Human Use (ICH) have played key roles in developing and consolidating GCP guidelines. While the WHO document serves as a global standard, the ICH guidelines focus on enhancing the quality and efficiency of pharmaceutical development and registration processes, facilitating the acceptance of the scientific aspects and procedures by both pharmaceutical companies and the regulatory agencies of the United States (FDA), Europe (EMA), and Japan (MHLW). Both sets of guidelines have been adopted by numerous countries, placing responsibility for their application on all involved in research, including investigators, sponsors, regulatory authorities, and participants.[18][19]

Stakeholders and roles in GCP

Understanding the various stakeholders involved in Good Clinical Practice (GCP) is essential for ensuring the integrity and ethical conduct of clinical research. Each participant in the process—ranging from regulatory agencies to individual participants—plays a critical role in upholding the principles of GCP.

- Regulatory agency: A competent body with the authority to regulate, review clinical information, and conduct inspections.

- Sponsor: Individual, company, institution, or organization responsible for initiating, administering, or funding a study.
- Ethics Committee: Assumes responsibility for reviewing and overseeing ethical aspects of a study.
- Contract research organization: Entity to which the sponsor transfers some study activities and obligations.
- Auditor: Conducts systematic reviews to ensure compliance with GCP and applicable regulations.
- Researcher: Qualified individual responsible for conducting the study and ensuring participant rights and safety.
- Sub-researcher: Study team member designated by the investigator to perform critical procedures or make study-related decisions.
- Participant: Individual receiving investigational drug product or serving as a control in the study.
- Impartial witness: Independent person present during the informed consent process.
- Monitor: Designated individual who monitors and reports on the study's progress and data verification to the sponsor or contract research organization.

To the extent possible, the principles of GCP should be applied generally to all clinical research involving human subjects, not just research involving pharmaceuticals or other medical products.[20]

Good Laboratory Practices (GLP)

Good Laboratory Practices (GLP) were established in response to unethical practices in research and development activities by pharmaceutical companies and facilities. The US FDA and Environmental Protection Agency (EPA) were among the first to implement GLP regulations, leading to their adoption by numerous other countries. The OECD also published GLP Principles, and the WHO issued guidelines for National Pharmaceutical Control Laboratories.

GLP encompasses **rules and criteria for quality systems related to the organizational processes and conditions governing non-clinical environmental health and safety studies.** It aims to ensure the

integrity of safety data, proper study management, and valid experimental results, thereby promoting drug safety and increasing the credibility of reported data to regulatory authorities.

GLP compliance is essential for ensuring the honest reporting of safety data, and it supports the mutual acceptance of test data between countries, thereby reducing testing duplication and costs while contributing to human health and environmental protection. It applies to chemical procedures for determining test stability, mixtures, homogeneity, and concentration.[21][22][23][24]

Good Documentation Practices (GDocP)

In recent years, there has been a growing emphasis on good documentation practices (GDocP) during Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Laboratory Practice (GLP) inspections, **driven by concerns about data reliability and appropriate control strategies.** GDocP, utilized in the pharmaceutical, laboratory, and manufacturing industries, encompasses best practices for creating and maintaining documentation. While not specifically regulated, its components are cited by federal and international agencies such as the Food and Drug Administration (FDA), the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), and the World Health Organization (WHO). Effective documentation is crucial for ensuring data integrity, aligning with the ALCOA and ALCOA+ principles (which state that data should be Attributable, Legible, Contemporaneous, Original and Accurate). These principles are used by the WHO, FDA, and other regulatory agencies to define the attributes of quality documentation.[25][26][27][28]

Good Pharmacovigilance Practice (GPvP)

Pharmacovigilance, as defined by the World Health Organization (WHO), **encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects and other drug-related problems.** Its scope extends to various

medical products and interventions, with objectives including ensuring patient care and safety, improving public health, detecting problems related to medication use, and contributing to evaluating the benefits, harm, effectiveness, and effects of medicines. GPvP promotes the safe, rational, and effective use of medicines, including cost-effectiveness, and emphasizes raising awareness, education, and training in pharmacovigilance and effective communication to the public. Additionally, it aims to guarantee the accuracy of collected data, ensure confidentiality, and maintain uniform criteria for evaluating notifications and generating signals or warnings.[29][30]

To develop pharmacovigilance activities, several methods are used:

- **Spontaneous notification system:** Also known as the "yellow card system", this method is widely used in pharmacovigilance. It involves the identification and detection of suspected adverse reactions by health professionals in their daily practice, with the information centralized and reported to a designated organization. This methodology is utilized by the participating centers of the WHO International Pharmacovigilance Programme.
- **Intensive pharmacovigilance procedures:** This method involves the systematic and detailed collection of data on all adverse effects that may be presumed to be induced by medicines in specific population groups. These procedures are categorized into medicine-centric systems and patient-centered systems.
- **Epidemiological studies:** These studies aim to establish causality and verify hypotheses related to adverse effects. They include cohort studies and case-control studies.

In Europe, Good Pharmacovigilance Practices (GVP) were established in 2012 by the European Medicines Agency (EMA) and were designed to facilitate and ensure pharmacovigilance in European Union countries. In contrast, in the United States, the Food and Drug Administration (FDA) published guidelines in 2005, but unlike the EMA's GVP, the FDA

guidelines are not legally binding. This means that while companies are encouraged to follow these GPvPs, they are not obliged to do so.[31]

Good Storage Practice (GSP)

Good Storage Practices (GSP) are essential for ensuring the integrity and safety of pharmaceutical products throughout their shelf life. These practices involve implementing appropriate methods to prevent contamination and deterioration during storage. Proper storage is a critical responsibility of pharmacists, as it helps maintain the chemical, physical, microbiological, and bio-pharmaceutical properties of medications within specified stability limits.[1][32]
To effectively support good storage practices, storage areas must be designed or adapted to maintain the stability of pharmaceutical products. They should be spacious enough to accommodate the organized storage of various categories of materials and products, including starting and packaging materials, intermediate products, bulk and finished products, and those that are quarantined, rejected, returned, or recalled.[33]

Furthermore, GSPs must comply with established labeling conditions, and several key factors must be taken into account for proper storage, such as temperature control, humidity levels, and protection from light and contamination. By prioritizing good storage practices, pharmacists can ensure that pharmaceutical products remain safe and effective throughout the distribution process.



Label	Store at controlled room temp.	Store in a cold or cool place	Store in a refrigerator	Store in a freezer	Store in deep freezer	Store in a dry place
WHO advice	15 to 25°C	8 to 15°C	5± 3°C	-20± 5° C	-70 ± 10 °C	No more than 60% relative humidity
Label	Protect from moisture	Store under ambient conditions		Protect from light		Chilled
WHO advice	No more than 60% relative humidity	Store in well-ventilated premises at temperatures of between 15 °C and 30 °C and no more than 60% relative humidity. Extraneous odours, other indications of contamination and intense light must be excluded.		To be maintained in the original manufacturer's light-resistant containers.		5± 3°C

The World Health Organization indicates that manufacturers should provide appropriate conditions for medical devices during storage. Manufacturers Claims such as storing at ambient conditions should be avoided. Whenever possible, manufacturers should specify actual limits, such as storing below 25 °C.[34]

Good Trade and Distribution Practices for pharmaceuticals (GTDP)

In 2000, the International Conference on Harmonization (ICH) published guidelines for Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients, which included specific provisions in Section 17 for agents, brokers, traders, distributors, repackagers, and relabelers. This section was developed following the World Health Organization's (WHO) investigation into fatalities linked to the mislabeling of industrial-grade ethylene glycol as pharmaceutical-grade material. At the time, WHO's existing GMP guidelines did not encompass aspects of good trade and distribution practices.[35]

In 2010, WHO revised its GMP guidelines to include the principles outlined in ICH Section 17. The WHO Expert Committee has since convened to discuss the guidelines for the trade and distribution of pharmaceutical

starting materials, which apply to all ingredients used in medicinal product manufacturing, including active ingredients and excipients.

Pharmaceutical products face various risks at different stages of the supply chain, including purchasing, storage, repackaging, relabeling, transportation, and distribution.[36] Good distribution and marketing practices (GDMP) establish minimum standards that distributors must meet to maintain the quality and integrity of medicines throughout the supply chain. The Good Trade and Distribution Practices (GTDP) standards are designed to apply to all steps in this process, emphasizing the responsibility of each actor in the distribution chain.

Suppliers of pharmaceutical materials must ensure that transportation contract acceptors are aware of and adhere to appropriate conditions for storage and transport, verified through rigorous audits. Good practices in the pharmaceutical industry span all stages of drug development, reflecting regulatory bodies' efforts to establish comprehensive guidelines that protect consumers and ensure the safety of pharmaceutical products.[37]

Key elements of GxP Compliance Aspects in Pharmaceutical Practices

GMP

Good Manufacturing Practices (GMP) provide essential guidelines to ensure that pharmaceutical products are consistently manufactured and controlled according to quality standards and regulatory requirements. Manufacturers are responsible for ensuring that products are fit for their intended use and comply with marketing authorizations.

This involves the commitment of senior management and collaboration across departments. An adequate quality infrastructure, comprising organizational structure, procedures, processes, and resources, is crucial for effective quality management. Systematic actions must be implemented to guarantee that products meet established quality requirements throughout the manufacturing process.

These guidelines apply to the production of drugs in their finished dosage forms and can be adapted to suit individual company needs.[38]

GCP

Good Clinical Practice (GCP) guidelines are designed to protect research participants and ensure the quality of the data obtained in clinical trials. These guidelines outline fourteen principles that provide guidance and assistance for their application and implementation by all parties involved in the clinical research process.[39]

The 14 principles of GCP generally offer guidelines for establishing research processes and systems, as well as defining the roles and responsibilities of various stakeholders.

GCP principles are intended to apply to all clinical research involving human subjects. While some principles may not be relevant to all types of human subjects' research, it is strongly recommended that these principles be considered whenever applicable to ensure the ethical, methodologically sound, and accurate conduct of research involving human participants.[40]

GLP

Good Laboratory Practices (GLP) guidelines ensure compliance across pharmaceutical laboratories, promoting international harmonization and cooperation. The guidelines encompass four key parts:

1. Management and Infrastructure: Focuses on establishing a management structure that supports quality functions and documentation, ensuring personnel and infrastructure align with the laboratory's activities.

2. Materials, Equipment, Instruments, and Devices: Reagents and materials used must meet quality standards. Equipment and instruments should be designed, calibrated, and maintained according to laboratory operational requirements.

3. Working Procedures: Emphasizes the importance of documented procedures for drug quality studies. Laboratories should implement analytical procedures to accurately identify substances and assess drug purity, in line with national quality programs.

4. Safety: Requires that all staff receive comprehensive safety training addressing identified hazards. Safety instructions should be regularly updated through written materials, displays, and seminars to promote ongoing compliance.[41][42]

GDocP

Good Documentation Practices (GDocP) are vital for ensuring that documentation meets high-quality standards throughout its lifecycle. The core principles, often referred to as ALCOA, dictate that documentation must be: Attributable, Legible, Contemporaneously recorded, Original, and Accurate.

To enhance documentation quality, the ALCOA-plus framework includes additional attributes: Complete, Consistent, Durable, and Available. Following these guidelines is crucial for organizations to maintain the accuracy, completeness, consistency, and reliability of their records and data. Adherence to GDocP ensures that all documentation remains valid and trustworthy throughout its entire period of usefulness.[28]

GPvP

Good Pharmacovigilance Practices encompass several key elements to ensure effective monitoring of drug safety and efficacy:

1. Diffuse: When a pharmacovigilance center begins operations in a country, significant efforts in dissemination are necessary to engage a substantial proportion of professionals in the field.

2. Administrative Continuity: If the center is part of a larger organization—such as a poison control unit, clinical pharmacology department, or hospital pharmacy—administrative continuity is crucial. This can be achieved by designating a professional, such as a pharmacist or physician, with primary responsibility for pharmacovigilance.

3. Government Resources: Pharmacovigilance should be closely linked to drug regulation, necessitating government resources for effective national coordination.

4. Collaboration, Coordination, Communication, and Public Relations: To promote coherent development and prevent overlapping competencies or unnecessary duplication of efforts, robust collaboration, coordination, communication, and public relations are essential.[43]

GSP

Good Storage Practices (GSP) provide essential guidelines to ensure the safe storage of pharmaceutical products. Key components include proper training for personnel, maintaining suitable premises and facilities, and establishing appropriate storage conditions. Continuous monitoring of these conditions is crucial for compliance.

Documentation is essential throughout all storage processes, including the receipt of incoming materials, stock rotation, and handling returned goods. Products must be clearly labelled and stored in suitable containers. Additionally, GSP outlines procedures for dispatch, transport, and product recalls to maintain quality and safety.

These guidelines apply to manufacturers, importers, contractors, wholesalers, and pharmacies, and should be tailored to the specific storage activities of each entity, in adherence to national or regional regulations.[44]

GTDP

Good Trade and Distribution Practices (GTDP) ensure the quality of pharmaceutical products is maintained throughout the trade and distribution process.[45] The guidelines cover several key aspects:

- Quality management
- Organization and personnel
- Premises
- Procurement, warehousing, and storage
- Equipment
- Documentation
- Repackaging and relabeling
- Complaints handling
- Returned goods
- Management of non-conforming materials
- Dispatch and transport
- Contract activities

The quality policy should clearly state that the distributor implements and maintains the GTDP guidelines within its organization and services. These WHO guidelines apply to all ingredients used in drug manufacturing, including active ingredients, excipients, and other materials.[46]

III. Overview of Global Regulatory Guidelines for Good Pharmaceutical Practice

Various official regulatory statements and guidelines on Good Pharmaceutical Practice exist at both at national and international levels. Many of these regulations are established by international organizations such as the World Health Organization (WHO), the International Conference on Harmonization (ICH), and the Pharmaceutical Inspection Cooperation Scheme (PIC/S). It is important to recognize that these guidelines are general in nature and can be adapted to fit the specific situations and conditions of each country.[2][27]

Mandatory use of best practice guidelines, according to different regulatory agencies.



The basic principle of pharmaceutical companies is that they must manufacture drugs so that they are suitable for their intended use. That is why the industry is at the forefront of GxP compliance, where compliance with stakeholder standards is ensured. Good practices

apply to almost every area of a company, from research and development to production, quality control, storage and distribution. Therefore, anyone who manufactures, tests, stores or markets drugs or APIs for commercial purposes must apply a set of defined requirements.[47]

International Regulatory Entities and Cross-Regional Collaboration in Pharmaceutical Oversight

The pharmaceutical sector is one of the most regulated industries due to the diverse range of products, the challenges in assessing their quality, safety, and efficacy, and the complexities involved in their development and production. Regulatory bodies, therefore, play a crucial role in ensuring that only legally marketed products are safe, effective, and of high quality.

Good Manufacturing Practices (GMP) originated in the United States as a response to issues in pharmaceutical production, establishing guidelines to ensure product quality. The development of these guidelines required collaboration among various organizations, regulatory authorities, and the pharmaceutical industry to reach a consensus on best practices.

As globalization and international trade have expanded, the need for consistent global quality standards has become increasingly important. GMP standards now encompass all organizations involved in drug development, marketing, manufacturing, and distribution. All stakeholders in the healthcare and pharmaceutical sectors are committed to understanding and applying GMP guidelines to uphold compliance with established standards. Notably, several influential organizations have emerged internationally, serving as key references for GMP.[3][48][49][50][51][52][53]

Key International Organizations Influencing GMP Guidelines

WHO

From its inception, the World Health Organization (WHO) has supported Good Manufacturing Practices (GMP) by publishing guidance texts and promoting their application in the pharmaceutical industry. The first draft of WHO's GMP guidelines was adopted in 1968, followed by the recommendation of the WHO Certification Scheme in 1969. These guidelines were further expanded between 1989 and 1990, and today, over 100 countries have integrated WHO GMP guidelines into their national drug regulations. WHO GMPs are published in the Technical Report Series (TRS) and have evolved over time, becoming more comprehensive and complex.[50][54][55][56]

ICH

The International Conference on Harmonization (ICH) is distinctive in uniting regulatory authorities and the pharmaceutical industry to discuss scientific and technical issues and to develop guidelines. While ICH does not directly modify Good Manufacturing Practices (GMP), it promotes a new understanding of them through scientific criteria, risk management, and lifecycle approaches. As the pharmaceutical sector has become more globalized, ICH guidelines have been adopted by an increasing number of regulatory authorities.[3][50][57]

PIC/S

Founded in 1995, the Pharmaceutical Inspection Cooperation Scheme (PIC/S) emerged from the Pharmaceutical Inspection Convention (PIC), established in 1970 by the European Free Trade Association (EFTA) to promote mutual recognition of inspections in pharmaceutical manufacturing. PIC/S facilitates cooperation and constructive activities in the field of Good Manufacturing Practices (GMP) with the primary goals of implementing, developing, and maintaining harmonized GMP standards and quality inspection systems for medicinal products.

The organization enhances collaboration and trust among competent authorities and regional and international organizations, with all decisions made unanimously. Currently, PIC/S comprises 52 authorities from various continents and has played a pioneering role in pharmaceutical inspections and GMP. It has effectively adapted to the evolving landscape of globalization. As of 2023, PIC/S will extend its mandate to encompass Good Practices (GxP).[3][58][59][60]

ISPE

The International Society for Pharmaceutical Engineering (ISPE) is a not-for-profit association that serves its members by leading scientific, technical and regulatory advances across the entire pharmaceutical life cycle.

ISPE focuses on connecting pharmaceutical knowledge to provide manufacturing and supply chain innovation, operational excellence and regulatory expertise to enhance the industry's efforts to develop, manufacture and reliably deliver quality medicines to patients. ISPE is represented by professionals from areas such as engineers, microbiologists, chemists, quality control, production, process development, pharmacists, regulatory and training personnel, academics and suppliers.[61]

IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) collaborates closely with public health stakeholders within the United Nations system, including the World Health Organization (WHO), the World Trade Organization (WTO), and the World Intellectual Property Organization (WIPO). IFPMA also partners with governments, global health organizations, non-governmental organizations (NGOs), civil society, patient groups, international hospital organizations, global foundations, and academic institutions.

For over 50 years, IFPMA has served as a bridge between the innovative pharmaceutical industry and various stakeholders in the global health community, facilitating dialogue and collaboration to address public health challenges.[62]

ISO

The International Organization for Standardization (ISO) brings together global experts to establish best practices across various industries since its inception in 1946. As one of the oldest international non-governmental organizations, ISO facilitates trade and cooperation worldwide. It publishes International Standards that cover a broad range of industries, including pharmaceuticals.

Key ISO certifications applicable to the pharmaceutical industry include:

- ISO 9001
- ISO 14001
- ISO 45001
- ISO 50001

ISO also implements a series of Identification of Medicinal Products (IDMP) standards designed to harmonize the way medicinal products are referenced across the pharmaceutical industry. The five IDMP standards form a global identification system for medicinal products, enhancing cross-border healthcare and supporting electronic prescriptions. The standards are:

ISO also implements a series of Identification of Medicinal Products (IDMP) standards designed to harmonize the way medicinal products are referenced across the pharmaceutical industry. The five IDMP standards form a global identification system for medicinal products, enhancing cross-border healthcare and supporting electronic prescriptions. The standards are:

- ISO 11238: Substances
- ISO 11239: Dosage forms, dosage routes, and packaging
- ISO 11240: Units of measurement
- ISO 11615: Regulated drug information
- ISO 11616: Regulated information on pharmaceuticals

Initially published in 2012 and subsequently updated, these standards facilitate the exchange of pharmacological information and play a crucial role in pharmacovigilance and compliance. Given that a significant percentage of active pharmaceutical ingredients and finished dosage forms in the U.S. are imported, the importance of a harmonized approach to global identification is essential. ISO IDMP standards are being adopted globally, with commitments from regulatory authorities in the U.S., Canada, Switzerland, and interest expressed from Japan, Australia, Russia, and Iran.[63][64][65][66]

FARMA COPEA

Pharmacopoeias are authoritative texts that provide comprehensive information on drugs and their formulations, including descriptions, analytical compositions, physical constants, chemical properties, identification standards, purity, and dosage guidelines. Typically published under governmental authority, pharmacopoeial standards are crucial for the marketing authorization, market surveillance, and global trade of medicines.

The International Pharmacopoeia serves as a resource for WHO Member States, offering recommended procedures for analyzing active pharmaceutical ingredients, excipients, and finished products. It focuses on monographs relevant to low- and middle-income countries that may lack the resources to develop national pharmacopoeias.

To promote harmonization of pharmacopoeial standards, the Pharmacopoeia Discussion Group (PDG) was formed in 1989, initially including the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP), and the United States Pharmacopoeia Convention (USP). WHO joined as an observer in 2001. In late 2021, the PDG launched a pilot project to expand recognition of harmonized pharmacopoeial

standards, initiating a one-year pilot phase with the Indian Pharmacopoeia Commission (IPC) in October 2022. In October 2023, the IPC was welcomed as a full member of the PDG, which continues to explore avenues for efficient functioning and further expansion. [51]

Collaboration Among Regional Regulatory Bodies

There is an ongoing dialogue between international organizations and governments regarding the balance between public safety and the economic activity generated by the pharmaceutical industry. Governments, through drug regulatory authorities—whether as independent regulatory agencies or specific drug regulatory bodies—establish and maintain rules, laws, and policies to ensure that drugs, including pharmaceuticals, vaccines, and biological products, are safe, effective, and meet quality specifications.

Pharmaceutical products manufactured under Good Manufacturing Practices (GMP) must comply with guidelines from national regulatory agencies, which are often based on international or regional compendia. For instance, the World Health Organization (WHO) provides general guidelines for GMP, which many countries adapt to create their own requirements. Some regions, such as the Association of Southeast Asian Nations (ASEAN) and the European Union, have harmonized their GMP standards, while others follow the Pharmaceutical Inspection Convention.
To further harmonize regulations, the pharmaceutical industry engages in strategic cross-regional collaborations, working with regulators on key issues such as managing complex supply chains, conducting inspections, and addressing quality defects. These collaborations facilitate regulatory efforts by allowing reliance on inspections from member countries and waiving batch testing, enabling pharmaceutical companies to adopt robust business practices that enhance cash flow. Furthermore, discussions among regulatory authorities from different countries foster trust and collaboration, helping them tackle common

challenges and advance global development programs. [48][67][68][69][70][72]

The following table provides a detailed overview of the main collaborations between regional regulatory authorities in the pharmaceutical sector.

Collaborations between regional regulatory authorities

Cluster Activities (European Medicines Agency	Established in 2004, the cluster activities of the European Medicines Agency (EMA) bring together experts from various regulatory authorities, including the U.S. Food and Drug Administration (FDA), Health Canada, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and the Australian Therapeutic Goods Administration (TGA). The main objective of these clusters is to discuss issues related to the safety and efficacy of pharmaceutical products, enhancing understanding of different regulatory approaches and facilitating aligned regulatory conclusions and actions. Participants in these discussions include scientific experts, regulatory affairs professionals, and managers. Meetings are held as teleconferences, with frequency and duration determined by each cluster. Over time, several clusters focusing on diverse therapeutic areas or product types have been formed, addressing topics such as advanced therapies, biosimilars, pediatric medicine development, rare diseases, and patient engagement.[73]
Gulf Central Committee for drug Registration	The Gulf Cooperation Council (GCC) Council of Ministers of Health established a study group in 1976 to create a centralized record review system for drug marketing and develop common guidelines. This led to the formation of the Gulf Central Committee for the Registration of Medicines in 1999, which includes two representatives from each member state. The committee´s main function is to register pharmaceutical companies andauthorize safe, effective, and high-quality medicinal products through a centralized procedure. The GCC comprises seven Gulf countries: the United Arab Emirates, Bahrain, Saudi Arabia, Oman, Qatar, Kuwait, and Yemen. Key objectives of the Gulf Central Committee include: - Unifying systems and procedures related to the registration of

medical companies and their products across GCC countries.
Ensuring adherence to Good Manufacturing Practices (GMP) and standardizing medicine prices in the region.
Activating post-marketing follow-up programs to monitor product quality and side effects, thereby enhancing integration.
Coordinating efforts among member states regarding medical products.
Implementing a Gulf Product Classification system based on unified definitions and standards.[74][75]

Asia Pacific Economic Cooperation

The Asia-Pacific Economic Cooperation (APEC) Forum was established in 1989 to capitalize on the growing interdependence of the region's economies. Comprising 21 economies, APEC initiated the Life Sciences Innovation Forum (LSIF) in 2002 to drive health and innovation in health sciences. The LSIF engages representatives from government, industry, and academia to foster a supportive policy environment for life sciences innovation, inviting contributions from organizations such as the World Health Organization and the World Bank.

In 2007, APEC established the Health Working Group (HWG) to highlight the importance of health for economic growth and to promote awareness of the returns on investment in health innovation. Subsequently, in June 2009, the LSIF formed the Regulatory Harmonization Steering Committee (RHSC) to promote regulatory harmonization. The RHSC consists of regulatory experts from APEC economies, industry, and academia, aiming for greater regulatory convergence without developing new guidelines.

The RHSC identifies Priority Work Areas (PWAs) within the medical products, pharmaceuticals, and medical devices sectors, focusing on areas where member economies can benefit from regulatory alignment.[76][77][78][79]

African Medicines Regulatory Harmonization Program

The African Medicines Regulatory Harmonization (AMRH) program was established in 2009 to address challenges faced by National Medicines Regulatory Authorities (NMRAs) in Africa, including inefficiencies, limited technical capacity, and slow drug registration processes. These issues hinder access to essential medicines and contribute to inflated drug prices.

The program aims to harmonize drug regulation and improve access to quality, safe, effective, and affordable medicines across the continent, aligning with the African Union's Pharmaceutical Manufacturing Plan for Africa (PMPA) Framework. The AMRH is supported by the African Union Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) and the World Health Organization (WHO). Currently, the AMRH comprises 26 member countries, promoting collaboration and regulatory improvements in the region.[80]

The Pan American Network for the Harmonization of Pharmaceutical Regulatory Affairs

Established in 2000 by the Pan American Health Organization (PAHO) Board of Directors, the Pan American Network for Drug Regulatory Harmonization (PANDRH) aims to support the harmonization of pharmaceutical regulation across the Americas, taking into account national and sub-regional health realities and addressing existing disparities in regulatory practices.

The network has several key objectives:

- Strengthening the regulatory functions and systems of member countries by promoting cooperation and exchange among national regulatory authorities, PAHO, and other organizations.
- Developing and implementing common proposals, including technical documents and guidelines, to advance regulatory convergence in health technology.
- Building core competencies to enhance good regulatory practices and the application of regulatory sciences in member states.[81]

Closing

Basic regulatory authorities and policies are essential for the implementation and enforcement of any pharmaceutical policy in the public or private sector. The publication of best practices by governments not only provides manufacturers, distributors, and retailers with clear guidance for action; it also provides regulators with clear guidelines for monitoring the market and implementing policies that will help develop a market for medicines and at the same time facilitate innovation and access to safe, effective, and good-quality medical products.[48][82]

There is currently an ongoing dialogue between industry and government on the scope of the maximum guidelines for harmonization of good drug practices that are applied in each country. This harmonization facilitates compliance with GMP, which is considered the best way to do business in the pharmaceutical industry, helping to eliminate trade barriers, improve technical cooperation, and increase cost savings in the testing and evaluation processes, supporting free market competition, and information transformation, and providing a prudent balance between public safety and the economic activity generated by the relatively profitable pharmaceutical industry. [67][83]

It is worth mentioning that GMP requirements were designed to be flexible. For the most part, they are very general in that they describe the minimum standard that a drug manufacturer or importer must meet in both its manufacturing, and marketing processes. In this way, each manufacturer can decide individually how best to implement the necessary controls. Additionally, the joint work of all organizations involved in the development, marketing, manufacturing and distribution of medicines is already implementing extensive measures in internal quality systems and risk management procedures that go beyond these minimum standards.[84][85]

The impact of COVID - 19

The COVID-19 pandemic highlighted the importance of having regulations in place to ensure product asepsis throughout the drug research and development process.[56] It is clear that the pandemic affected the management and operation of regulatory agencies and the pharmaceutical industry worldwide due to the closing of borders between countries, which prevented APIs from reaching pharmaceutical manufacturing sites and even led to shortages in low- and middle-income countries.[86]

This prompted regulatory authorities to consider new ways of working by introducing, among other things, remote inspections to validate the integrity of regulatory data submitted by companies, assess the quality of production and manufacturing sites, and ensure compliance with good regulatory practices, with the overall aim of ensuring patient safety during the crisis that was constrained by the disruption of supply chains, particularly for essential medicines. This was an important development because a fairly large proportion of active pharmaceutical ingredients (APIs) and pharmaceuticals are currently produced and procured in developing countries.[87]

In today's dynamic regulatory landscape, resilient methods and partners are essential to overcoming future logistical challenges. Our next white paper will explore the strengths and obstacles of pharmaceutical logistics hubs and why Panama has become a resilient hub in recent years. Additionally, it will discuss how Panama is equipped to meet current pharmaceutical logistics needs.

Stay tuned for the final installment in this series!

Notes

[1]Organización Panamericana de la Salud. (2008, May). Directrices para las pruebas de estabilidad de productos farmacéuticos que contienen sustancias medicamentosas bien establecidas en formas farmacéuticas orrientes . https://www3.paho.org/hq/dmdocuments/2008/5_Anexo_5_del_informe_34.pdf

[2]World Health Organization. (2006). Good distribution practices for pharmaceutical products. https://www.fda.gov.ph/wp-content/uploads/2021/03/World-Health-Organization-Good-Distribution-Practices.pdf

[3]Gouveia, B. G., Rijo, P., Gonçalo, T. S., & Reis, C. P. (2015). Good manufacturing practices for medicinal products for human use. Journal of pharmacy & bioallied sciences, 7(2), 87–96. https://doi.org/10.4103/0975-7406.154424

[4]EUPATI. (2020, August 14). Autorización de comercialización - EUPATI Toolbox. EUPATI Toolbox. https://toolbox.eupati.eu/glossary/autorizacion-de-comercializacion/?lang=es

[5]A Brief History of the GMPs. (n.d.). biomanufacturing.org. https://biomanufacturing.org/uploads/files/305429596362804820-brief-history-of-gmps.pdf

[6]SAVALnet - Normas GMP en la fabricación de medicamentos: ser o no ser. (2003, September 1). SAVALnet. Retrieved March 25, 2024, from https://www.savalnet.cl/mundo-medico/reportajes/1398.html

[7]Research, C. F. D. E. A. (2024, February 16). Facts About the Current Good Manufacturing Practice (CGMP). U.S. Food And Drug Administration. https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp

[8]Choudhary, A. (2023, August 8). Concept of GxP in Pharmaceuticals. Pharmaguideline. https://www.pharmaguideline.com/2017/01/concept-of-gxp-in-pharmaceuticals.html

[9]Velasco, C. (2023, November 7). Buenas Prácticas en Industria Farmacéutica - Guía. Cercal Group Especialistas En La Industria Farmacéutica. https://cercal.cl/envinculo/buenas-practicas-en-industria-farmaceutica/

[10]Deloitte. (n.d.). The challenge of compliance in life sciences. deloitte.com. https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/lshc-challenge-of-compliance.pdf

[11]Priest, S. (2023, December 8). GxP Compliance and Good Documentation Practice. Ardington Archives. https://ardingtonarchives.co.uk/gxp-compliant/

[12]MHRA. (2018, March). Medicines & Healthcare products Regulatory Agency (MHRA). https://assets.publishing.service.gov.uk/media/5aa2b9ede5274a3e391e37f3/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf

[13]Tobin C. Guarnacci. (2022). Introduction to GxP Quality Management Systems . ivi.int. https://www.ivi.int/wp-content/uploads/2023/02/Guarnacci-Tobin_Intro-to-GxP-quality-management-systems.pdf

[14]WHO. (2014, October 1). TRS 986 - Annex 2: WHO good manufacturing practices for pharmaceutical products: Main principles. https://www.who.int/publications/m/item/trs986-annex

[15]Pan American Health Organization (PAHO). (n.d.). Prácticas adecuadas de fabricación de productos farmacéuticos.
https://www3.paho.org/hq/dmdocuments/2008/1_Anexo_1_informe_32.pdf

[16]What is GMP? (n.d.). ISPE | International Society for Pharmaceutical Engineering.
https://ispe.org/initiatives/regulatory-resources/gmp/what-is-gmp

[17]Academy, E., & Academy, E. (2023, June 21). What ist GMP? https://www.gmp-compliance.org/what-is-gmp

[18]Vijayananthan, A., & Nawawi, O. (2008). The importance of Good Clinical Practice guidelines and its role in clinical trials. Biomedical imaging and intervention journal, 4(1), e5. https://doi.org/10.2349/biij.4.1.e5

[19]Osorio, L. (2015, February 2). Lo que todos debemos saber de las buenas prácticas clínicas. Biomedica.
https://doi.org/10.7705/biomedica.v35i2.2404

[20]WHO. (2005). HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP).
https://iris.who.int/bitstream/handle/10665/43392/924159392X_eng.pdf?sequence=1

[21]World Health Organization . (2012, March). GOOD LABORATORY PRACTICE TRAINING MANUAL. proto.ufsc.br.
https://proto.ufsc.br/files/2012/03/glp_trainee_green.pdf

[22]PAHO. (2010). Buenas prácticas de la OMS para laboratorios de control de calidad de productos farmacéuticos . www3.paho.org.
https://www3.paho.org/hq/dmdocuments/2011/Espanol-control-calidad-laboratorios-farmaceuticos.pdf

[23]Good laboratory practice compliance | European Medicines Agency. (n.d.).
https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-laboratory-practice-compliance

[24]Food and Drug administration. (2007). Good Laboratory Practices Questions and Answers . www.fda.gov.
https://www.fda.gov/media/75866/download

[25]eupati. (2021). Key GxPs in Medicine. EUPATI Open Classroom.
https://learning.eupati.eu/mod/book/tool/print/index.php?id=661

[26]Patel, K., & Chotai, N. (2011). Documentation and Records: Harmonized GMP Requirements. Journal of young pharmacists : JYP, 3(2), 138–150. https://doi.org/10.4103/0975-1483.80303

[27]Protection, O. F. H. S. (2024, February 7). Good Documentation Practices (GDP) - Office for Human Subject Protection - University of Rochester. Office for Human Subject Protection.
https://www.rochester.edu/ohsp/resources/study-documentation/gdp/

[28]WHO. (2016, June 15). Guidance on good data and record management practices.
http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_996_ANNEX05.PDF

[29]Organización Panamericana de la Salud. . (2010, December). Buenas Prácticas de Farmacovigilancia para las Américas.
https://www3.paho.org/hq/index.php?option=com_docman&view=download&alias=33513-buenas-pra-cticas-farmacovigilancia-ame-ricas-2010-513&category_slug=documentos-8499&Itemid=270&lang=es

[30]FDA Group. (2023, January 3). Good Pharmacovigilance Practices (GVP): A Quick-Guide.
https://www.thefdagroup.com/blog/good-pharmacovigilance-practices-gvp-a-quick-guide

[31]Eunice Arcilla Caburao. (2023, December 13). A Guide to Good Pharmacovigilance Practice | SafetyCulture. SafetyCulture. https://safetyculture.com/topics/good-pharmacovigilance-practice/

[32]Shafaat, Hussain, Kumar, Hasan, Prabhat, & Yadav. (2013, October). AN OVERVIEW: STORAGE OF PHARMACEUTICAL PRODUCTS. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2(5, 2499–2515). https://www.researchgate.net/publication/258833887_AN_OVERVIEW_STORAGE_OF_PHARMACEUTICAL_PRODUCTS

[33]WHO. (2003). Annex 9 Guide to good storage practices for pharmaceuticals. https://www.fda.gov.ph/wp-content/uploads/2021/03/World-Health-Organization-Good-Storage-Practices.pdf

[34]WHO. (2020, June 17). Annex 7: Good storage and distribution practices for medical products. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs1025-annex7-(1).pdf?sfvrsn=1f96888d_4&download=true

[35]WHO. (2016, October 10). Good trade and distribution practices for pharmaceutical starting materials. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs996-annex06-good-trade-and-distribution-practice-for-starting-materials914a3c92-e15d-420d-859a-34f666a6c659.pdf?sfvrsn=71e466ca_2&download=true

[36]WHO. (2019, August). GOOD STORAGE AND DISTRIBUTION PRACTICES FOR MEDICAL PRODUCTS. https://iris.who.int/bitstream/handle/10665/330887/DI332-194-225-eng.pdf

[37]WHO. (2006). Good distribution practices for pharmaceutical products. https://www.fda.gov.ph/wp-content/uploads/2021/03/World-Health-Organization-Good-Distribution-Practices.pdf

[38]WHO. (2014, October 1). TRS 986 - Annex 2: WHO good manufacturing practices for pharmaceutical products: Main principles. https://www.who.int/publications/m/item/trs986-annex

[39]Osorio, L. (2015, February 2). Lo que todos debemos saber de las buenas prácticas clínicas. Biomedica. https://doi.org/10.7705/biomedica.v35i2.2404

[40]WHO. (2005). HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP). https://iris.who.int/bitstream/handle/10665/43392/924159392X_eng.pdf?sequence=1

[41]WHO. (2005). WHO guidelines for sampling of pharmaceutical products and related materials. World Health Organization. https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs929-annex4-guidelinessamplingpharmproducts.pdf?sfvrsn=f6273f30_2

[42]PAHO. (2010). Buenas prácticas de la OMS para laboratorios de control de calidad de productos farmacéuticos . www3.paho.org. https://www3.paho.org/hq/dmdocuments/2011/Espanol-control-calidad-laboratorios-farmaceuticos.pdf

[43]Organización Panamericana de la Salud. . (2010, December). Buenas Prácticas de Farmacovigilancia para las Américas. https://www3.paho.org/hq/index.php?option=com_docman&view=download&alias=33513-buenas-pra-cticas-farmacovigilancia-ame-ricas-2010-513&category_slug=documentos-8499&Itemid=270&lang=es

[44]WHO. (2003). WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs1025-annex7-(1).pdf?sfvrsn=1f96888d_4&download=true

[45]WHO. (2019, August). GOOD STORAGE AND DISTRIBUTION PRACTICES FOR MEDICAL PRODUCTS. https://iris.who.int/bitstream/handle/10665/330887/DI332-194-225-eng.pdf

[46]WHO. (2016, October 10). Good trade and distribution practices for pharmaceutical starting materials. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs996-annex06-good-trade-and-distribution-practice-for-starting-materials914a3c92-e15d-420d-859a-34f666a6c659.pdf?sfvrsn=71e466ca_2&download=true

[47]Academy, E., & Academy, E. (2023, June 21). What ist GMP? https://www.gmp-compliance.org/what-is-gmp#gmpmand

[48]PAHO & 2022. (2022). Buenas prácticas regulatorias en la regulación de productos médicos. https://iris.paho.org/bitstream/handle/10665.2/57165/9789275327555_spa.pdf?sequence=7&isAllowed=y

[49]A. (2024, Jan uary 8). ¿Qué es la normativa GMP? Significado y aplicación en la industria - Alvinox. Alvinox. https://www.alvinox.com/que-es-la-normativa-gmp-significado-y-aplicacion-en-la-industria

[50]STE ENGIPHARM. (2022, May 3). Evolución de los principios básicos de las GMP de la OMS para productos farmacéuticos. STE Engipharm. https://www.steengipharm.com/principios-basicos-gmp-oms/

[51]edqm. (n.d.). Pharmacopoeial Harmonisation - European Directorate for the Quality of Medicines & HealthCare - EDQM. European Directorate for the Quality of Medicines & HealthCare. Retrieved April 25, 2024, from https://www.edqm.eu/en/pharmacopoeial-harmonisation

[52]2. About Good “x” Practice (GxP) | EUPATI Open Classroom. (n.d.). https://learning.eupati.eu/mod/book/tool/print/index.php?id=660#_ftn3

[53]Abdellah, A., Noordin, M. I., & Wan Ismail, W. A. (2015). Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 23(1), 9–13. https://doi.org/10.1016/j.jsps.2013.06.003

[54]Historia Acerca de la OMS. (n.d.). https://www.who.int/es/about/history#:~:text=En%20abril%20de%201945%2C%20durante,conferencia%20para%20redactar%20su%20constituci%C3%B3n.

[55]WHO. (2016, August 19). WHO good manufacturing practices for biological products, Annex 2, TRS No 999. https://www.who.int/publications/m/item/annex-2-trs-no-999-WHO-gmp-for-biological-products#cms

[56]Covarrubias, C., Rivera, T., Soto, C. D. A., Deeks, T., & Kalergis, A. M. (2022, November 3). Current GMP standards for the production of vaccines and antibodies: An overview. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2022.1021905

[57]CH Official web site : ICH. (n.d.). Retrieved April 22, 2024, from https://www.ich.org/

[58]PIC/S. (n.d.). History of PIC/S. Retrieved April 22, 2024, from https://picscheme.org/en/history

[59]PIC/S. (n.d.). LIST OF PIC/S PARTICIPATING AUTHORITIES. Retrieved April 22, 2024, from https://picscheme.org/en/members?paysselect=AR

[60]PIC/S. (n.d.). International Co-operation. Retrieved April 22, 2024, from https://picscheme.org/en/about-international-co-operation

[61]About ISPE. (n.d.). ISPE | International Society for Pharmaceutical Engineering. Retrieved May 30, 2024, from https://ispe.org/about

[62]IFPMA. (2023, February 27). About us - IFPMA. Retrieved April 24, 2024, from https://www.ifpma.org/about-us/

[63]ISO - About ISO. (n.d.). ISO. https://www.iso.org/about-us.html

[64]Garry Lambert. (2016, June 23). Pharma sector gets new ISO tool for drug identification. ISO. https://www.iso.org/news/2016/06/Ref2092.html

[65]ISO. (2016). ISOfocus. https://www.iso.org/files/live/sites/isoorg/files/news/magazine/ISOfocus%20(2013-NOW)/sp/isofocus_115.pdf

[66]Garry Lambert. (2016, March 7). Curbing death and injury with safer medication. ISO. https://www.iso.org/news/2016/03/Ref2056.html

[67] Signore, A. (2005). Good Design Practices for GMP Pharmaceutical Facilities (By T. Jacobs). http://repo.upertis.ac.id/1822/1/Good%20Design%20Practices%20for%20GMP%20Pharmaceutical%20Facilities.pdf

[68]OPS/OMS . (n.d.). Control de calidad de medicinas. OPS/OMS | Organización Panamericana De La Salud. Retrieved April 26, 2024, from https://www.paho.org/es/temas/control-calidad-medicinas

[69]Research, C. F. D. E. A. (2024, February 16). Facts About the Current Good Manufacturing Practice (CGMP). U.S. Food And Drug Administration. https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp

[70]European Medicines Agency. (2023, December 9). https://www.ema.europa.eu/en/partners-networks/international-activities/bilateral-interactions-non-eu-regulators/united-states

[71]Realizing tangible value from strategic alliances, JV's and partnering arrangements. (n.d.). PwC. Retrieved April 30, 2024, from https://www.pwc.com/il/en/pharmaceuticals/strategic-alliances.html

[72]Teixeira, T., Kweder, S. L., & Saint-Raymond, A. (2020). Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?. Clinical pharmacology and therapeutics, 107(3), 507–513. https://doi.org/10.1002/cpt.1617

[73]European Medicines Agency. (n.d.). Cluster activities | European Medicines Agency. Retrieved April 29, 2024, from https://www.ema.europa.eu/en/partners-networks/international-activities/cluster-activities

[74]GHC Landing. (2023, July 6). Central registry - GHC Landing. GHC Landing - GHC. https://www.ghc.sa/en/central-registration/

[75]Hashan, H. M., Al-Muteb, S. K., Alismail, I. A., Alsaleh, O. N., Alkherb, Z. M., McAuslane, N., & Walker, S. R. (2022). Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality. Pharmaceutical medicine, 36(4), 223–231. https://doi.org/10.1007/s40290-022-00432-0

[76]APEC. (2024, January). Health Working Group | APEC. https://www.apec.org/groups/som-steering-committee-on-economic-and-technical-cooperation/working-groups/health

[77]De Aduanas, S. N. (2007, February 28). Foro de Cooperación Económica de Asia Pacífico (APEC). Aduana. https://www.aduana.cl/foro-de-cooperacion-economica-de-asia-pacifico-apec/aduana/2007-02-28/103547.html#:~:text=El%20Foro%20de%20Cooperaci%C3%B3n%20Econ%C3%B3mica,en%20la%20regi%C3%B3n%20Asia%2DPac%C3%ADfico.

[78]APEC. (n.d.). About us. Retrieved April 29, 2024, from https://www.apec.org/RHSC/About-us

[79]APEC. (2024, January). Health Working Group | APEC. https://www.apec.org/groups/som-steering-committee-on-economic-and-technical-cooperation/working-groups/health

[80]AMRH. (n.d.). Who We Are | AUDA-NEPAD- AMRH. Retrieved April 30, 2024, from https://amrh.nepad.org/amrh-microsite/who-we-are

[81]Weisfeld, V., Lustig, T. A., & Translation, F. O. D. D. D. A. (2013, October 24). Overview of the Current Global Regulatory Landscape. International Regulatory Harmonization Amid Globalization of Drug Development - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK174229/

[82]Pezzola, A., Sweet, C.M. Global pharmaceutical regulation: the challenge of integration for developing states. Global Health 12, 85 (2016). https://doi.org/10.1186/s12992-016-0208-2

[83]ISPE. (2019, January 23). Good Manufacturing Practice (GMP) Resources. ISPE | International Society for Pharmaceutical Engineering. https://ispe.org/initiatives/regulatory-resources/gmp#:~:text=GMP%20covers%20all%20aspects%20of,quality%20of%20the%20finished%20product.

[84]HEALTH-MED. (2022, May 7). GMP compliance in pharmaceutical industry – the importance of GMP regulations - Blog - Healthmed. https://www.health-med.info/blog/gmp-compliance-in-pharmaceutical-industry-the-importance-of-gmp-regulations,p1973839444

[85]EUPATI Open Classroom. (n.d.). About Good “x” Practice (GxP) https://learning.eupati.eu/mod/book/tool/print/index.php?id=660#_ftn3

[86]Dukart, H., Patel, P., Telpis, V., & Yngve, J. (2020, April 9). Pharma operations: Creating the workforce of the future. McKinsey & Company. https://www.mckinsey.com/industries/life-sciences/our-insights/pharma-operations-creating-the-workforce-of-the-future

[87]Mofid, S., Bolislis, W. R., Brading, C., Hamilton, N., Hardit, C., Nagaoka, M., Parain, J., Zanta, M., & Kühler, T. C. (2021). The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting. Clinical therapeutics, 43(12), 2046–2063. https://doi.org/10.1016/j.clinthera.2021.10.003



About the **Why Panama** Program

In the current dynamic global landscape, it is clear that having access to high-quality insights is crucial when determining the optimal location for regional distribution in order to take advantage on the present structure of global value chains.

Georgia Tech Panama Logistics Innovation & Research Center recognizes the importance of key insights in the decision-making process, and works closely with companies seeking to assess their supply chains and how Panama can become a key part of their global logistics network.

The "Why Panama" program utilizes quantitative data and analytics to assess key variables and compare the costs, investments, and service benefits of setting up a distribution center in Panama. By conducting a thorough analysis, the program aims to provide businesses with valuable insights into the advantages of establishing a hub in Panama.

To know more you can contact Jeancarlos Chen at **jeancarlos.chen@gatech.pa** or Jorge Barnett at **jorge.barnett@gatech.pa**

WRITTEN BY

Ricardo Espinoza

EDITED BY

Jorge Barnett

Jeancarlos Chen

Sahian Rosales

ILLUSTRATED BY

Belén Rivas

Eric Wu

About Us

The Georgia Tech Panama Logistics Innovation and Research Center is located in Panama City, Panama. It was launched in 2010 by an agreement between the Georgia Institute of Technology and the Goverment of Panama through the National Secretariat of Science, Technology and Innovation (SENACYT).

Georgia Tech Panama
Logistics Innovation & Research Center

An innovation center of SENACYT
Secretaría Nacional de Ciencia, Tecnología e Innovación

CONTACT US

(+507) 395-3030

georgiatechpanama@gatech.pa

gatechpanama